Emoxypine (Mexidol)vsReishi

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine succinate) has a 3-hydroxypyridine structure similar to vitamin B6 (pyridoxine). It is one of the most potent inhibitors of lipid peroxidation in brain tissue — it scavenges hydroxyl radicals and peroxyl radicals, inhibits Fe2+-induced lipid peroxidation, and may chelate transition metals. It modulates the GABA-benzodiazepine receptor complex (GABA-A), enhancing GABAergic transmission through positive allosteric modulation — possibly at a site distinct from the classical benzodiazepine binding site, explaining the lack of sedation and tolerance. It improves mitochondrial function (Complex I protection, membrane stabilization), stabilizes cell membranes (reducing fluidity changes during oxidative stress), and enhances cerebral microcirculation (possibly via nitric oxide or prostaglandin modulation). The anxiolytic mechanism may involve partial agonism or different subunit selectivity.

Reishi's triterpenes (ganoderic acids A, C, D, H; ganoderenic acids) modulate the HPA axis by reducing CRH and ACTH release, lowering cortisol via glucocorticoid receptor feedback. Ganoderic acids have direct sedative effects through GABA-A receptor modulation (possibly allosteric at the benzodiazepine site) and 5-HT2A/2C serotonergic modulation. Beta-(1,3)-(1,6)-glucan polysaccharides bind Dectin-1 and complement receptor 3 (CR3) on macrophages, natural killer cells, and dendritic cells, activating NF-kB and MAPK signaling for immune modulation. Reishi inhibits histamine release from mast cells via Fc epsilon RI downregulation and stabilizes mast cell membranes (anti-allergic effect). Antioxidant properties involve upregulation of superoxide dismutase (SOD1/SOD2), catalase, and glutathione peroxidase. Ganoderic acids may also inhibit 5-alpha-reductase and ACE.